Lupin Pharmaceuticals Inc, the US unit of Lupin Ltd, has received US FDA approval for its supplemental New Drug Application (sNDA) to expand the use of secnidazole in the treatment of bacterial vaginosis for female patients 12 years of age and older and for the treatment of trichomoniasis for all patients 12 years of age and older. Bacterial vaginosis is a common vaginal infection and trichomoniasis is the most common non-viral, curable sexually transmitted infection in the U.S. The supplemental adolescent approval enhances the drug’s (branded as SOLOSEC) strong position as the first and only single-dose oral prescription antimicrobial agent for these diseases.